Richard M Heaslip

US Patent:

20020198201, Dec 26, 2002

Filed:

Jun 6, 2002

Appl. No.:

10/164214

Inventors:

Thomas Privette - Villanova PA, US
Richard Heaslip - Newtown PA, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K031/5377
A61K031/4439
A61K031/405
A61K031/381
A61K031/343

US Classification:

514/232800, 514/337000, 514/339000, 514/415000, 514/443000, 514/469000

Abstract:

This invention provides methods for utilizing a PTPase inhibiting compounds and an aldose reductase inhibitor, including, but not limited to Minalrestat Tolrestat, Sorbinil, Methosorbinil, Zopolrestat, Epalrestat, Zenarestat Imirestat, and Ponalrestat, in methods for use in control and maintenance of type II diabetes in a mammal, for improving the cardiovascular and cerebrovascular risk profiles, reduction of, diabetic neuropathy, hyperlipidemia, lowering low density lipoprotein blood levels, lowering free fatty acid blood levels and triglyceride levels and inhibition, prevention or reduction of atherosclerosis in a type II diabetic, or the risk factors thereof.

US Patent:

50029495, Mar 26, 1991

Filed:

May 1, 1990

Appl. No.:

7/517099

Inventors:

Steven M. Peseckis - Plainsboro NJ
Jehan F. Bagli - Princeton NJ
Richard J. Heaslip - Newtown PA
Thomas J. Colatsky - Devon PA

Assignee:

American Home Products Corporation - New York NY

International Classification:

A61K 31505
C07D23902

US Classification:

514256

Abstract:

A compound of the formula: ##STR1## in which R. sup. 1 is --OH or --NH. sub. 2 ; R. sup. 2 is a halogen or --CN; R. sup. 3 is a halogen or --CN; and n is one of the integers 1, 2 or 3; or a pharmaceutically acceptable salt thereof, are useful as antithrombotic agents.